Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SMARCE1 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-07 |
mRNA | ARID1A | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-07 |
mRNA | C7orf55-LUC7L2 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
mRNA | ZNF737 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-07 |
mRNA | ZNF232 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-07 |
mRNA | TBC1D28 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-07 |
mRNA | POLD1 | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-07 |
mRNA | TSPYL4 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-07 |
mRNA | GATAD2B | CTRPv2 | pan-cancer | AAC | 0.19 | 5e-07 |
mRNA | TMED3 | CTRPv2 | pan-cancer | AAC | -0.17 | 5e-07 |